54 results about "In vitro binding" patented technology

An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

The present invention relates to an [18F]fluoromethyl group-introduced radiotracer for positron emission tomography for targeting brain neuroinflammation, a synthesis thereof, and a method for evaluating biological results using the same. In the present invention, a fluoromethyl group-introduced fluorine-18 labeled radiotracer was prepared by introducing [18F]fluoroiodomethane, in which a prosthetic group diiodomethane is labeled with fluorine-18, into PBR28-OH through two stages, or substituting fluorine-18 using a triazolium triflate precursor in one stage at high yield. It was confirmed that, as a result of comparison and evaluation with exiting known [11C]PBR28 in view of in vitro binding affinity, fat affinity, and pharmacodynamic characteristics in a brain neuroinflammation model, the fluoromethyl group-introduced fluorine-18 labeled radiotracer had similar binding affinity and fat affinity to [11C]PBR28. Further, it was confirmed from the PET image comparison and evaluation in the brain neuroinflammation model that the fluoromethyl group-introduced fluorine-18 labeled radiotracer exhibited excellent selective / specific absorption in the inflammatory region more quickly and had high stability at the brain neuroinflammation site. According to the present invention, with respect to the synthesis of the novel fluoromethyl group-introduced fluorine-18 labeled radiotracer for PET targeting brain neuroinflammation and the diagnosis of brain neuroinflammation diseases, fluorine-18 having a relatively longer half-life than [11C]PBR28 was capable of being excellently labeled through the minimum structural change, and its excellent selective and specific imaging and pharmacodynamic advantages were verified, and thus a useful radiotracer for PET targeting brain neuroinflammation can be expected.

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

The invention belongs to the technical field of gene engineering and particularly relates to a DypB active protein heterology high expression method and application. Aiming at the problem that existing DypB protein has no activity in hyterology expression and only can generate activity by being combined with heme in vitro, the invention provides the DypB active protein heterology high expression method and application. The method disclosed by the invention comprises the steps of integrating related genes expressing the heme into host cells through genetic recombination to enable a host to have high-concentration heme, then constructing DypB into a recombinant vector and leading the recombinant vector into an expression host with high heme expression; thus, heterology high expression of the DypB active protein can be achieved. According to the method disclosed by the invention, the heme is integrated in the expression host to be synthesized into the related genes to improve the in-vivo accumulation concentration of the heme, then the DypB is expressed a lot through a cold induction mode, and the DypB has activity for degrading lignin after being expressed by the host.

The invention discloses a construction method for distinguishing a model of the activity effect of PBDEs derivatives on enoyl-ACP reductase. The construction method comprises the steps of receptor andligand modeling, molecular docking and molecular dynamics simulation. The calculation result of the model is consistent with the result of an in-vitro binding activity determination experiment, and the result shows that the construction method of the model can accurately calculate the activity effect of the PBDEs derivatives on the enoyl-ACP reductase.

The invention discloses an O-type foot-and-mouth disease CTL epitope peptide, a screening method and application thereof. The CTL epitope peptide is composed of nine amino acid residues, and its amino acid sequence is: Ala-Thr-Arg-Val-Thr-Glu-? Leu-Leu-Tyr. The epitope peptide can have strong binding ability with SLA-I proteins derived from different strains of pigs and can cause cytotoxic immune response, and is suitable for the preparation of vaccines for the prevention and treatment of various strains of porcine foot-and-mouth disease viruses, and has a wide range of applications. The invention uses the constructed six-strain pig SLA-I single-chain molecule to bind the CTL mimetic epitope peptide of foot-and-mouth disease virus in vitro, mass spectrometry to screen the polypeptide that can bind to the complex, and through ELISPOT detection, it is determined that it can induce T cell immune response Capable mimotope peptides. The invention provides a method for screening and identifying a large number of CTL epitopes of foot-and-mouth disease virus in the future, and lays a foundation for developing a porcine foot-and-mouth disease multi-epitope vaccine.

The invention discloses a myrtle polysaccharide P3, its separation and purification method and its use in the preparation of blood lipid-lowering drugs. The polysaccharide contains the following molar percentages of monosaccharides: 9.97% of ribose, 2.40% of rhamnose, and 64.51% of arabinose , xylose 6.14%, mannose 5.39%, glucose 1.74%, galactose 9.85%. The experimental results of the present invention show that myrtle polysaccharide P3 has a certain ability to bind bile salts in vitro. With cholestyramine as a positive control, the binding rate of cholestyramine to each bile salt is calculated as 100%. The relative binding rates of myrtle polysaccharide P3 to sodium taurocholate, sodium glycocholate, and sodium cholate were 29.65%, 45.84%, and 51.90%, respectively.

The invention provides an arsenic binding protein A10, a recombinant vector containing a coding gene of the protein and an engineering strain containing the recombinant vector. The arsenic binding protein A10 disclosed by the invention can be used for improving the resistance of a strain to arsenite and methyl arsenite, improving the accumulation efficiency of the strain to the arsenite and the methyl arsenite and combining the arsenite and the methyl arsenite in vitro. The engineering bacterium has strong resistance to arsenite and methyl arsenite, the binding efficiency of the target protein A10 to arsenite and reducing monomethyl arsenic is as high as 92.24% and 76.69%, the binding efficiency of the target protein A10 to arsenite and reducing monomethyl is as high as 96.70% and 83.33%, and arsenic in a culture environment can be effectively removed. The protein A10 with strong binding capacity to arsenite and methyl arsenite provides a novel bioremediation material for arsenic pollution remediation in paddy fields and water environments.